Market Talk: Opportunity, Strength, and Speculation

  

Market Talk 

The market pulled back over the past two weeks, mostly on the idea that the Fed might skip the December rate cut many had expected. That was enough to shake things out a bit. Since then, a few Fed officials have hinted that the economy still supports a cut, which helped steady the tone. For Jones readers who kept some powder dry, the dip may have opened the door to nibble on select tech and defense names. If buying back in, small batches and inching in still look like the prudent approach.

Stock  Talk 

With gold and silver holding firm and both metals sitting well above the levels most banks predicted for this year, the miners that actually deliver real grades and real cash flow are starting to separate from the pack. Two names stand out:

Hecla Mining Company (HL)

Hecla turned in a strong update across all three of its key sites. Midas (Nevada) hit high-grade gold with visible gold in the core, running from roughly 30 g/t up to over 200 g/t in the best pockets, with surrounding intervals in the 4–10 g/t range. Keno Hill (Yukon) added more silver zones, including the usual 80–200 g/t silver that fills out the system. Greens Creek (Alaska) confirmed additional ore in active areas, consistent with the strong silver, gold, zinc, and lead grades that make it one of the better producers in North America.
The grades at all three sites are high overall and show potential for high-value expansions at mines that are already highly productive.

Kinross Gold Corporation (KGC)

We don’t even need higher gold prices here. Kinross produces at low costs, and with gold holding well above what even Goldman Sachs predicted ($2,700), KGC stands out. They’re posting steady earnings, buying back shares, cutting debt, and raising dividends. That combination makes it one of the better stocks in the sector — and for that matter, the entire market.
On top of that, KGC has exposure to fresh exploration upside through its involvement with junior companies now trading at penny-stock levels, including Relevant Gold (RGCCF) in Wyoming and Puma Exploration (PUMXF) at the Williams Brook Gold Project in New Brunswick, Canada. These early-stage districts add inexpensive optionality that could matter over time.

Bottom Line

Earnings and growth are the key fundamental drivers, and both HL and KGC are showing those traits right now. That’s the hallmark of a stock worth watching, and it’s why both continue to stand out on the Jones report.

Speculation Corner – Oncolytics Biotech (ONCY)

ONCY, as a $1 penny stock may fit best as a “some stock” — an interesting speculative name, but not a “too much” stock. The company now has initial FDA alignment for a pivotal Phase 3 pancreatic cancer trial, which can draw attention from big pharmas whose checkpoint inhibitors struggle in cold-tumor cancers like pancreatic, ovarian, prostate, MSS-colorectal, and GBM. If a partner steps up, it could put the other checkpoint companies on alert — and once that happens, that’s where a pop could come from.
__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Special Jones Report — ONCY, Pelareorep, and Why a Buyout Scenario Is Back on the Table

  

The $1 Stock Holding a Potential $20 Billion Solution for Big Pharma’s Cold-Tumor Gap

Key Opinion Story:

Strong and growing evidence and data is showing that Pelareorep is the immune activator cold tumors have been missing. It is the naturally occurring, cancer-targeting virus that Oncolytics Biotech (ONCY)has learned to amplify — slipping into tumor cells, lysing them from within, exposing antigens, and triggering the T-cell activation cold tumors cannot produce on their own. In immunotherapy, that is the spark.

Checkpoint inhibitors, marketed by the Pharma giants, do not kill cancer. They block the suppressive proteins — PD-1, PD-L1, CTLA-4 and others — that tumors use to disable T-cells. The T-cells do the actual attacking, but only once they’ve been activated and driven into the tumor with force.

Pelareorep activates those T-cells and brings them to the tumor. Checkpoint inhibitors remove the blocks that were stopping those T-cells from working. That is why Pelareorep is a strategic asset, not an incremental add-on.

There’s also the quiet possibility that an early low-ball offer already came in — likely from a large pharma without a checkpoint program, testing whether ONCY would sell Pelareorep on the cheap. Instead of folding, ONCY locked in its Phase 3 design with the FDA, a classic move to raise the valuation floor and send a message: come back with real money. And that’s where the story shifts, because once the Phase 3 path was secured, the real intrigue moves to the companies with heavy checkpoint stakes on the line.

Pelareorep unlocks cold tumors, and the pharma that owns it will be the only one with a checkpoint that actually works there. Merck and BMS are the obvious examples — and several other pharmas with checkpoint ambitions are watching just as closely.

If Merck owns Pelareorep, Keytruda dominates cold tumors.
If BMS owns it, Opdivo gains a second life where checkpoints currently fail.
If both hesitate, other checkpoint players — Roche, AstraZeneca, Pfizer/Seagen — have every reason to step in and reshape the field.

This is not a minor asset. Major oncology platforms routinely command $10–$20+ billion deals, and Pelareorep fits the platform category, not the bolt-on category. Cold tumors remain one of the biggest failures in modern immunotherapy, and Pelareorep is one of the first credible solutions.

ONCY trades today as a $1 penny stock, dismissed by skeptics who stare at the price instead of the science and strategy. But the price does not change the fundamentals. The FDA’s alignment with ONCY on the Phase 3 pancreatic cancer design puts Pelareorep directly in view of companies whose checkpoint franchises depend on solving the cold-tumor problem.

Markets often miss the obvious. This might be one of those times.

Market Talk 

The market feels jumpy again. AI stocks are back in the news with big earnings, and people are already arguing whether this run is the real thing or just another bubble forming. These tech bursts can lift the whole market for a day or two, but then they fade right back into the same choppy selloffs we’ve been seeing. The money comes in fast and leaves just as fast.

Meanwhile, the real economy hasn’t changed — inflation still hangs around, the world is a mess, and traders are reacting to every headline like it’s the next crisis. That’s why the resource names still matter. Gold and silver don’t depend on hype or perfect conditions. They sit underneath all the noise, and eventually the market comes back to them when things get shaky.

Today’s sudden market turn doesn’t feel great to most people holding stocks, but the bigger story hasn’t changed just yet. These kinds of selloffs show up fast, and they usually settle once the panic eases. Nothing in the fundamentals broke — the market just got loud again.

Not every story in the market moves with the indices. Some move on science, not sentiment. ONCY fits that lane. While the tape is shaky, the work behind Pelareorep continues, and the latest FDA alignment puts the spotlight back where it belongs — on whether the data can change outcomes in a cancer with very few options.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Stock Talk Update on Hecla Mining, Kinross Gold, and ONCY — Is BMS the Dark Horse?

  

Market Talk 

NVDA gave the market another lift, powered by the nonstop AI buildout and its latest round of strong earnings. Tech names jump back into the spotlight fast, but the leadership never stays in one place for long. What does stay steady is the resource story — real demand, real supply pressure, and none of the hype cycles. That’s why names like Hecla and Kinross remain mainstays here, even when the market is busy chasing whatever tech star lit up the headlines this week. Sometimes the best trades are the ones that don’t need headlines at all.

Stock Talk 

Hecla Mining (HL)

Hecla is one of the few solid U.S. silver producers in a market where China is tightening export controls to keep more silver at home for its vast solar-panel manufacturing and expansive military-equipment buildouts. That means less silver coming out of China and more focus on dependable North American supply. With global silver demand rising and supply tightening, Hecla’s position only gets stronger. Add in gold by-product production from its U.S. mines and the Casa Berardi gold mine in Canada, and Hecla remains a mainstay in the Jones view, with breakout potential still to be seen. It appears to be a good stock to hold and possibly accumulate on dips.

Kinross Gold (KGC)

With gold holding near the $4,000 range, Kinross stands out as one of the steadier names in the gold sector. The company keeps costs low, throws off solid cash flow, and continues to reward shareholders with buybacks and dividend increases instead of dilution. Even if gold dips from these levels, KGC’s all-in sustaining costs are low enough that earnings still look solidly positive. Kinross is also taking a smart, lower-risk expansion path by partnering with junior explorers in high-grade potential plays like RGCCF and PUMXF, all operating in safe North American mining regions. As long as gold stays firm — and even if it softens — KGC’s disciplined strategy and strong cost position give it plenty of room to keep delivering.

Speculation Corner — ONCY (and BMS?)

ONCY just shifted gears with the FDA’s alignment on its Phase 3 pancreatic trial. The design is agreed to, and Pelareorep’s cancer-lysing and immune-activating profile is now in front of regulators — a milestone that finally puts real structure behind the PDAC program.

The bigger angle? The checkpoint players. Keytruda has been everywhere, but checkpoints still struggle in cold-tumor settings like pancreatic, ovarian, and several other solid cancers where ALL the checkpoints usually fail. Opdivo (BMS) is in the same situation — results and sales in these tough cancers have been slower than hoped. If Merck drags its feet, BMS is known to move faster when a new drug can make their checkpoint work in places it normally falls flat. Pelareorep is that kind of immune primer — the piece that turns a “cold” tumor into something a checkpoint can actually attack.

And this is where the story gets bigger. When a small biotech holds something that could strengthen multiple big-pharma checkpoint franchises, you’re not just looking at partnership potential — maybe even buyout potential starts creeping in. Big pharma doesn’t like watching competitors gain the upper hand in cancers they’ve been failing to crack for years. ONCY — it’s a company to watch closely. Here at the Jones Report, we use the word maybe on speculation — maybe some.

Ramaco Resources struggles in a coal mindset

Ramaco Resources with it's METC and METCB has been pushed back into the coal bucket by the market, despite the rare-earth potential sitting under the Brook Mine. The stock is acting like a pure coal play and is being priced that way. The rare-earth story hasn’t clicked with investors because Washington hasn’t moved, the defense sector hasn’t leaned in publicly, and investors don’t reward “potential” without partners or independently verified assays that change the narrative. Until that happens, Ramaco trades like a dog and gets valued like one. The long-term rare-earth opportunity may still be real, but for now it sits in the background rather than driving the stock.

Staying Nimble

In a market that swings from AI euphoria to resource strength and back again, keeping some dry powder never hurts. Some weeks it’s tech, some weeks it’s metals — but opportunity tends to show up for those who stay flexible.  When the headlines get louder and the swings get wider, having room to move can matter more than making the perfect call.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

Reading Signals in a Noisy Market - KGC, HL, METCB and ONCY

    

Market Talk 

The world gets weirder and stranger every day. A Marxist-leaning mayor in New York City, war grinding on in Ukraine, sticky inflation from years of lingering Biden inflation, overspending, and China hinting at rare-earth pressure while trade policy shifts week to week. At the same time, the major indices keep bouncing around their highs, with volatility throwing some stock  into ten-percent swings — plenty of charts look stretched. Finding a way to gain leverage on gold and silver may be the smarter play these days.

But at this point, we’ve already seen some nice gains, and while the trend still looks steady, it’s not always easy to stay steadfast with that stretched feeling hanging over trader sentiment. Still, the miners are holding their ground, and plenty of investors think we may be on the verge of a breakout that finally recognizes the growth these companies are showing in their earnings results.

Stock Talk 

Kinross Gold (KGC)

Kinross has stayed disciplined. With gold prices firm, their cash flow supports share buybacks and dividend bumps — not something you see often in a sector known for dilution. If gold simply holds steady, the lower share count alone gives KGC a natural lift, and management seems committed to rewarding shareholders instead of chasing expansion.

Hecla Mining (HL)

Hecla remains one of the cleanest plays on rising silver demand in the U.S. Silver stays tight thanks to solar, electronics, and data-center build-outs. Add in their gold by-product credits — which help lower operating costs — and HL has more breathing room than most silver producers. Their recent earnings already reflect what stronger metal prices can mean.

Rare Earths — A Story Waiting to Break Out?

President Trump keeps talking about securing rare-earths, but most of the attention is on foreign sources or “friend-shoring.” Meanwhile, our own domestic opportunities — especially the rare-earth potential in Ramaco’s Brook Mine in Wyoming — barely get mentioned. That’s where METC and METCB come in. If Washington takes a serious look at what’s sitting in our own backyard, Ramaco’s rare-earth angle could move from background chatter to headlines. If that happens, METC and METCB may find themselves in the spotlight for something far more valuable than coal.

Speculation Corner — ONCY

ONCY drew attention today after Anson filed a new 13G showing 7% ownership on the same morning HC Wainwright doubled their price target to $10 — a timing that feels like they may be sensing something the market hasn’t fully picked up on yet. The one question mark — the kind that could set a fire under the stock — is ONCY’s upcoming FDA design meeting. If the FDA raises the fairness issue about putting late-stage pancreatic patients into an old standard-of-care control arm — something the agency has questioned before in other deadly cancers — it could reshape the trial in a way investors, institutions, and even a few big pharmas with checkpoint drugs may not ignore.

Dry Powder

In a noisy market, keeping some dry powder and avoiding the all-in mentality is one way to stay nimble. When the headlines get louder and the swings get wider, having room to move can matter more than making the perfect call.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________

TWO Stocks: Kinross Gold Corporation (KGC) and Hecla Mining company (HL) - and penny stock corner on two others with Kinross eyes on them

   

Market Talk 

Much has happened since our last post.  The Fed cut rates, as expected, but also noted that a follow-on rate cut in December is uncertain as they try to monitor inflation in a government shutdown.  Then -we saw the elections that show further polarization of the country.  

The Markets have shown that although at all- time highs, individual stocks are stretched.  Meanwhile the fiat currencies are becoming more devalued, including the dollar.
Gold and silver prices, although bouncing around high thresholds are holding near all-time highs. 

Stock  Talk 

Two mining companies, as described in prior posts here, stand out as continued high performers,

Kinross Gold Corporation (KGC)

                    and,

Hecla MiningCompany (HL)

Speculation Corner penny stock - Relevant Gold (RGCCF)

Kinross recently exercised its warrants and boosted its stake in Relevant Gold (RGCCF). No fanfare, no hype — just a modest $2.9 million top-up and a show of quiet confidence.

Relevant trades around $0.30, a true penny stock with light volume — average about 38,000 shares a day. That means only small limit trades, and only for those willing to wait and speculate on what Kinross may also be seeing out there.

Relevant Gold – Wyoming Project Portfolio” map showing 40,000 + acres]

Kinross already knows this kind of ground. It built part of its success mining the same ancient, gold-bearing formations farther north. Wyoming’s belt offers that same geology inside the U.S. — stable laws, open ground, and less competition.

Relevant controls more than 40,000 acres across several projects, with mapped shear zones and visible gold at surface. For Kinross, a small investment secures a front-row seat on a big land story. The first drill results are due early next year. It’s a waiting game, thin volume and all, but sometimes that’s where the quiet setups start.

Update: PUMXF is another penny stock connected with Kinross Interest and backing that looks prospecting interesting at 12 cents a share.

https://finance.yahoo.com/news/puma-exploration-samples-126-g-130200758.html

_______

Disclosure:  Jones bought 5,000 shares of RGCCF with a limit order at $0.30 and 5,000 of PUMXF at $0.12 with the gamble alongside Kinross. The Jones Report has no affiliations or arrangements with any company mentioned here in StocksToWatch. This isn’t a pump site, just conversation about what’s out there — and what may or may not be.

__

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.This site does NOT make Buy / Sell recommendations.
________